ScientiaLux
Index
QF-Pro Home › QF-Pro Glossary › CXCL11
Chemokine

CXCL11

The highest-affinity CXCR3 ligand—with dual CXCR3/CXCR7 signaling and a paradoxical pro-tumor role in hormone receptor-positive breast cancer.

View
Definition
CXCL11 (Interferon-Inducible T cell Alpha Chemoattractant, I-TAC) is the highest-affinity ligand for CXCR3 among the three IFN-γ-inducible chemokines. Unlike CXCL9Loading... and CXCL10Loading..., CXCL11 also signals through CXCR7 (ACKR3), activating pAKT and pERK pathways. This dual receptor engagement gives CXCL11 a paradoxical role: while it recruits anti-tumor T cells via CXCR3, it can directly promote tumor cell proliferation through CXCR7-mediated signaling—making it the most potent of the three chemokines in driving estrogen-independent growth in HR+ breast cancerLoading... (Napolitano et al., 2026).
Highest Affinity
Strongest CXCR3 binding of the three ligands
Dual Receptor Signaling
Signals through both CXCR3 and CXCR7
Paradoxical Pro-Tumor Role
Drives estrogen-independent growth via pAKT/pERK
Th1 Polarization
Preferentially recruits Th1 and cytotoxic T cells

CXCR3/CXCR7 Dual Signaling

CXCL11's unique biology stems from its ability to engage two distinct receptors:

  • CXCR3: Shared with CXCL9Loading... and CXCL10Loading...—mediates T cell chemotaxis and Th1 immune polarization
  • CXCR7 (ACKR3): Unique to CXCL11 among the three—activates β-arrestin signaling, pAKTLoading..., and pERK in tumor cells

CXCR7 was originally classified as a "decoy" or scavenging receptor, but is now recognized as a signaling-competent receptor that activates pro-survival pathways. In HR+ breast cancer cells, CXCL11-CXCR7 signaling provides an estrogen-independent growth stimulus through AKT and ERK phosphorylation.

Simplified

Two Receptors, Two Effects:

• CXCR3: Recruits anti-tumor T cells (good for the patient)

• CXCR7: Activates tumor growth pathways pAKT and pERK (bad for the patient)

CXCL11 does both simultaneously—making its net effect context-dependent.

Paradoxical Dual Role in the TiME

CXCL11 exemplifies the context-dependent nature of immune-tumor interactions. In the TiMELoading..., CXCL11 simultaneously:

  • Recruits CD8+ T cells and Th1 cells via CXCR3—promoting anti-tumor immunity
  • Stimulates tumor cell proliferation via CXCR7—promoting tumor growth

The net outcome depends on the balance between these opposing forces. In immunotherapy-responsive tumors, T cell-mediated killing may dominate. But in HR+ breast cancerLoading... on endocrine therapy, the pro-proliferative effects may contribute to resistance by providing alternative growth signals when estrogen signaling is blocked.

Simplified

The Paradox: CXCL11 recruits the immune cells that kill tumors AND activates growth signals in tumor cells. Whether the net effect helps or hurts the patient depends on context.

In breast cancer: When hormone therapy blocks estrogen, CXCL11 may provide tumor cells an alternative growth signal—contributing to drug resistance.

Endocrine Resistance in Breast Cancer

Napolitano et al. (J Clin Invest. 2026;136(3):e188458) demonstrated that CXCL11 was the most potent of the three CXCR3 ligands in driving estrogen-independent proliferation of HR+ breast cancer cells. Key findings:

  • CD8+ T cell coculture conditioned media promoted HR+ tumor cell growth through CXCR3 ligands
  • CXCL11 drove the strongest proliferative response via pAKT and pERK activation
  • This effect was mediated through both CXCR3 and CXCR7 signaling
  • High CXCR3 ligand expression correlated with shorter relapse-free survival in endocrine-treated patients

This reveals a therapeutic vulnerability: the same immune response recruited to fight tumors may inadvertently fuel endocrine resistance through chemokine-mediated growth signaling.

Simplified

A Surprising Discovery: Napolitano et al. (2026) found that CD8+ T cells—the very immune cells fighting the tumor—produce chemokines that can make breast cancer cells grow without estrogen.

CXCL11 was the worst offender: It was the most potent growth-promoter of the three chemokines, activating AKT and ERK pathways that bypass hormone therapy.

Simple Recruitment Signal
Chemokines are passive directional cues—immune cell recruitment is inherently beneficial, and more T cells in the tumor always means better outcomes.
Context-Dependent Dual Agent
CXCL11 simultaneously recruits anti-tumor T cells and drives tumor proliferation via CXCR7-pAKT/pERK signaling—its net effect depends on therapeutic context, measurable by spatial proteomics.

Clinical Significance

  • Highest potency: Most potent driver of estrogen-independent growth among the three CXCR3 ligands (Napolitano et al., J Clin Invest. 2026;136(3):e188458)
  • Dual receptor signaling: CXCR3 + CXCR7 activation of pAKTLoading... and pERK bypasses endocrine therapy targets
  • CD8+ T cell paradox: Elevated in CD8+ T cell coculture conditioned media—immune cells inadvertently fueling resistance
  • Endocrine resistance biomarker: Potential marker for identifying HR+ breast cancerLoading... patients at risk of resistance to hormone therapy

Connected Terms

Share This Term
Term Connections